National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Idelalisib (Zydelig®)

Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

 

Rapid Review

Commenced Completed Outcome
08/12/2014 30/12/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
04/06/2015 16/02/2016 Reimbursement Not Recommended

Summary

The HSE has approved reimbursement following confidential price negotiations December 2016.